The GDG found insufficient evidence to recommend one route over another for the
prevention of PPH with oxytocin, the use of recombinant factor VIIa for the treatment
of PPH, intraumbilical vein injection of oxytocin for treatment of retained
placenta, and the antenatal distribution of misoprostol. The GDG also found insufficient
evidence to recommend self-administration for the prevention of PPH and the
measurement of blood loss over clinical estimation (